Personalized natural killer cell therapy for blood cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific blood cancer type (such as AML, ALL, MDS, NHL, CLL/SLL, CML, Hodgkin’s, or multiple myeloma).
- Your disease is in a certain risk/relapse situation (for example: not in first remission, or high-risk features in first remission).
- You must be between 15 and 45 years old (or up to 80 with a less intense treatment plan, depending on the study plan).
- Your heart, lung, kidney, and liver lab tests must meet minimum safety thresholds.
- A back-up source of blood stem cells must be available (from a relative or cord blood) in case the transplant support step doesn’t work.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This Phase 1 trial tests a specific chemotherapy plan followed by a reduced-intensity donor stem cell transplant for people with relapsed or treatment-resistant acute myeloid leukemia (AML), certain myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It may help by using donor stem cells to rebuild the bone marrow after intensive cancer treatment, in people who are not responding well to standard therapies.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
Hear when a new Acute Biphenotypic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.